POP Biotechnologies Awarded $2.46M NIH Grant for Alzheimer's Immunotherapy
October 1, 2025 POP Biotechnologies, Inc. (POP BIO), has been awarded a $2.46M USD grant by the National Institutes of Health (NIH) to pursue development of a “mosaic” active immunotherapy against Alzheimer’s disease (AD).
POP BIO and CEPI announce collaboration for faster responses to Disease X
July 24, 2025 POP BIO announces award of $1.5M award from CEPI to advance SNAP platform into development of a vaccine against severe fever with thrombocytopenia syndrome (SFTS).
POP BIO Announces Vaccine Concept Targeting Avian Influenza H5N1 Clade 2.3.4.4b
April 17, 2025
POP BIO Cancer Vaccine Concept Accepted into NCI Nanotechnology Characterization Program
February 26, 2025 POP Biotechnologies accepted into the NCI Nanotechnology Characterization Laboratory for evaluation of an ultra-potent cancer vaccine system for short MHC-I restricted synthetic peptides.
POP BIO awarded $2.84M Phase II SBIR for seasonal influenza vaccine development
November 26, 2024 POP Biotechnologies Inc. (POP BIO) received a $2.84M Phase II SBIR under award number 1R44AI181479-01, supported by the National Institute of Allergies and Infectious Disease (NIAID), part of the National Institutes of Health (NIH), to pursue the development of a unique vaccine approach against seasonal influenza.
POP Biotechnologies Announces Phase 3 Trial Interim Results Published for COVID-19 Vaccine Based on POP BIO SNAP™
September 27, 2024 BUFFALO, N.Y., September 27, 2024 - POP Biotechnologies (POP BIO), a Buffalo, NY-based biopharmaceutical company, is pleased to announce the publication of positive findings in a peer-reviewed paper in the Journal of Medical Virology entitled “Interim safety and immunogenicity analysis of the EuCorVac-19 COVID-19 vaccine in a Phase 3 randomized, observer-blind, immunobridging trial in the Philippines”.
POP BIO announces findings for an Alzheimer’s Disease polyvalent peptide immunotherapy
September 13, 2024 POP Biotechnologies has announced positive results for their pentavalent peptide vaccine targeting Alzheimer’s Disease, published in Brain Behavior and Immunity. The vaccine, utilizing POP BIO’s SNAP™ technology, demonstrated efficacy in mice by targeting multiple epitopes of amyloid-β and tau proteins, showing potential for treating early-stage AD. The vaccine is now advancing toward clinical trials through EuPOP Life Sciences, a joint venture with EuBiologics.
POP BIO and FunPep Announce Collaboration for Antibody-Inducing Peptide Therapy
August 21, 2024 POP Biotechnologies announces the furtherance of research with FunPep. Advanced preclinical testing of antibody-inducing peptides will be carried out.
POP BIO and EuBiologics’ Shingles Vaccine Enters Phase 1 Clinical Trials
August 7, 2024 POP Biotechnologies announces the commencement of dosing of the shingles vaccine “EuHZV” in collaboration with EuBiologics in a Phase 1 clinical study in Korea.
SNAP Platform Enters Phase I Clinical Studies for RSV
May 10, 2024 EuBiologics co.,Ltd has started Phase 1 testing of EuRSV, a next-generation RSV vaccine. This is now the second vaccine (after EuCorVac-19) to enter human testing based on University at Buffalo and POP Biotechnologies’ SNAP vaccine adjuvant system.
Janssen Vaccines collaboration with POP BIO’s SNAP vaccine platform results published in Nature Communications
April 12, 2024 POP Biotechnologies (POP BIO), a Buffalo, NY-based biopharmaceutical startup, announces the publication of new data involving a SNAP-based C HIV-1 Env vaccine available.
POP BIO and EuBiologics’ EuCorVac-19 COVID-19 vaccine hits target in Phase 3 trial
June 23, 2023 POP Biotechnologies (POP BIO), a Buffalo, NY-based biopharmaceutical startup, announces top line interim results of a Phase 3 clinical trial of EuCorVac-19.
POP Biotechnologies awarded $2M NIH-NCI Phase II STTR in collaboration with Roswell Park
February 1, 2023 POP Biotechnologies awarded $2M NIH-NCI Phase II STTR in collaboration with Roswell Park BUFFALO, N.Y. — POP Biotechnologies Inc. (POP BIO) received a $2M Phase II.
POP Biotechnologies’ SNAP Vaccine Platform Enters Large Scale Clinical Trials for COVID-19
November 30, 2022 POP Biotechnologies (POP BIO), a Buffalo, NY based biopharmaceutical startup, announces the approval of the plan for a phase 3 clinical study of EuCorVac-19, a COVID-19 vaccine candidate developed by South Korean partner EuBiologics (KOSDAQ: 206650, CEO, Dr. Baik YoungOk, Mr. Seukkeun Choi) from the Ministry of Food and Drug Safety in South Korea. EuCorVac-19, is a protein-based vaccine consisting of Eubiologics protein antigen, EulMT, in-licensed from Korea Institute of Science and Technology and the spontaneous-nanoliposome antigen particle (SNAP) technology of POP BIO.
POP Biotechnologies’ SNAP Vaccine System Safe and Effective in a Phase II Clinical Trial for COVID-19
November 30, 2022 POP Biotechnologies (POP BIO), a Buffalo, NY based biopharmaceutical startup, announces the approval of the plan for a phase 3 clinical study of EuCorVac-19, a COVID-19 vaccine candidate developed by South Korean partner EuBiologics (KOSDAQ: 206650, CEO, Dr. Baik YoungOk, Mr. Seukkeun Choi) from the Ministry of Food and Drug Safety in South Korea. EuCorVac-19, is a protein-based vaccine consisting of Eubiologics protein antigen, EulMT, in-licensed from Korea Institute of Science and Technology and the spontaneous-nanoliposome antigen particle (SNAP) technology of POP BIO.